The CD44 Antigen pipeline drugs market research report outlays comprehensive information on the CD44 Antigen targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the CD44 Antigen pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Genito Urinary System, and Dermatology which include the indications Breast Cancer, Gastric Cancer, Systemic Sclerosis (Scleroderma), Graft Versus Host Disease (GVHD), Acute Renal Failure (ARF) (Acute Kidney Injury), Scar, and Wounds. It also reviews key players involved in CD44 Antigen targeted therapeutics development with respective active and dormant or discontinued products.
The CD44 Antigen pipeline targets constitutes close to 12 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 3, 4, and 2 respectively. Similarly, the universities portfolio in Phase II, and Preclinical comprises 2, and 1 molecule.
CD44 Antigen overview
The CD44 antigen is a cell-surface glycoprotein that’s involved in cell adhesion, migration, and cell–cell interactions. It’s encoded by the CD44 gene on chromosome 11 in humans. CD44 is also known as lymphocyte homing receptor. CD44 is highly expressed in many cancers and regulates metastasis. Dysregulated CD44 expression characterizes most human cancers, including prostate cancer.
For a complete picture of CD44 Antigen’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
